MedTrace Logo

Ruxolitinib Treatment in Inclusion Body Myositis

NCT06536166 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-10-03

No results posted yet for this study

Summary

Refer to the "Detailed Description" section.

Conditions

  • Inclusion Body Myositis, Sporadic

Interventions

DRUG

Ruxolitinib

IBM patients treated by ruxolitinib (JAKAVI®), 15mg per os, twice a day, during 12 months.

DRUG

Placebo

IBM patients treated by placebo, twice a day, during 12 months.

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • François Jérôme AUTHIER, Pr · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-27
Primary Completion
2028-06-10
Completion
2028-09-10

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06536166 on ClinicalTrials.gov